Abstract
In patients with chronic obstructive lung disease bronchodilator therapy with the combination of theophylline and a β 2-agonist [1], theophylline and ipratropium bromide [2] and ipratropium bromide and a β 2-agonist [3] has been demonstrated to be more effective than treatment with either agent alone. Including ipratropium bromide into a combination therapy with theophylline and a β 2-agonist increases bronchodilatation without additional side effects [4].
This is a preview of subscription content, log in via an institution to check access.
References
Wolfe JD, Tashkin DP, Calvarese B, Simons M (1978) Bronchodilator effects of terbutaline and aminophylline alone and in combination in asthmatic patients. N Engl J Med 298: 363–367
Kreisman H, Frank H, Wolkove H, Gent M (1981) Synergism between ipratropium and theophylline in asthma. Thorax 36: 387–391
Bryant DH (1985) Nebulized ipratropium bromide in the treatment of acute asthma. Chest 88: 24–29
Rebuck AS, Gent M, Chapman KR (1983) Anticholinergic and sympathomimetic combination therapy of asthma. J Allergy Clin Immunol 71: 317–323
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag, Berlin Heidelberg New York
About this paper
Cite this paper
Villiger, B., Bezel, R., Brändli, P., Braun, P., Helcl, I., Haegi, V. (1987). Additive Effect of Sustained-Release Theophylline and Anticholinergic/ Sympathomimetic Therapy in Patients with Reversible Airflow Obstruction: Preliminary Results. In: Dethlefsen, U., Matthys, H. (eds) Fokus — Atemwegserkrankungen heute. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72768-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-72768-9_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17958-0
Online ISBN: 978-3-642-72768-9
eBook Packages: Springer Book Archive